Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Go back to Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations| (AMEX: MKKGY) | Delayed: 33.29 -0.26 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.55 | 52 Week High | $ | |||
| Open | $32.68 | 52 Week Low | $ | |||
| Day High | $33.48 | P/E | N/A | |||
| Day Low | $32.68 | EPS | $ | |||
| Volume | 168,623 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 128.66 +3.21 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $65.46 | |||
| Open | $125.83 | 52 Week Low | $47.97 | |||
| Day High | $128.78 | P/E | 87.52 | |||
| Day Low | $125.83 | EPS | $1.47 | |||
| Volume | 18,891,511 | |||||
